This review explores immune dysregulation and inflammation in dry eye disease, suggesting new therapeutic strategies.
Dry eye disease is increasingly recognised as a condition driven by immune dysregulation at the ocular surface. Chronic inflammation, mediated by aberrant activation of both innate and adaptive immune pathways, underlies disease progression and symptom persistence. Neuroimmune interactions further amplify ocular surface inflammation, contributing to epithelial damage and impaired homeostatic regulation. This review synthesizes current literature on the immunopathogenesis of dry eye disease (DED), highlighting the complex interplay of molecular mechanisms of innate and adaptive immune activation, neuroimmune-mediated inflammation, and emerging molecular and cellular biomarkers. In addition, we examine existing and emerging therapeutic strategies that target these immune-molecular pathways, including precision immunomodulatory approaches, to inform future management of DED. By integrating mechanistic insights with clinical findings, this review aims to provide a comprehensive overview of the molecular mechanisms underlying the dysregulated immune response associated with DED.
No takes yet. Share an insight, caveat, or question.
Saram et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: